Sang Do Lee, Woo Jin Kim, Won Yeon Lee, Heung Bum Lee, Yeon-Mok Oh, Yong Chul Lee, Nam Soo Yoo, Sang Haak Lee, Hye-Kyung Park, Won-Jung Koh, Mi Ok Kim, Sung Yeon Kwon, Byoung Whui Choi, Young Whan Kim, Kwang Ho In, Tae Hoon Jung, Woo Sung Kim, Suk Joong Yong, Sung Kyu Kim, Won Hyuk Shin, Soon Kew Park, Jee Hong Yoo, Cheon Woong Choi, Ju Ock Kim, Min Ki Lee, Hong Mo Kang, Sang Yeub Lee, Myung Sook Kim, Young-Chul Kim, Young Chun Ko, Young Sam Kim, Hyung Jung Kim, Kyung Rok Kim, Chae Man Lim, Dong Soon Kim, Young Soo Shim, Seung Joon Kim, Sung Soo Park, Mi Hye Kim, Kye Chul Shin, Yun Seong Kim, Yang Keun Rhee, Eun Hae Kang, Chang Youl Lee, Sung Hak Park, Chul Min Ahn, Young Kyoon Kim, Sung Soo Jung, Yang Deok Lee, Seung Ick Cha, Hyoung Suk Ham, Chul Gyu Yoo, Sung Koo Han, Hwa Sik Moon, and O Jung Kwon
Background : This study compared the bronchodilator efficacy and safety of tiotropium inhalation capsules ( once daily) with a ipratropium metered dose inhaler (2 puffs of q.i.d.) in patients with chronic obstructive pulmonary disease (COPD). Method : After the initial screening assessment and a two-week run-in period, patients received either tiotropium once daily or ipratropium four times daily over a period of 4 weeks in a double blind, double dummy, parallel group study. The outcome measures were the lung function, the daily records of the peak expiratory flow rate (PEFR), the patients' questionnaire, and the use of concomitant salbutamol. The forced expiratory volume in one second () and the forced vital capacity (FVC) were measured 5 minutes before inhalation, and 0.5, 1, 2 and 3 hours after inhaling the study drug on days 0, 14 and 28. Result : In 16 centers, 134 patients with a mean (SD) age of 66 (7) years and a predicted of 42 (12)% were analyzed. The trough response was significantly higher in the tiotropium group than in the ipratropium group after a four-week treatment period. The weekly mean morning PEFR of the tiotropium group was consistently higher than that of the ipratropium group during the 4-week treatment period with differences ranging from 12.52 to 13.88 l/min, which were statistically significant. Tiotropium was well tolerated by the COPD patients during the 4-week treatment period and had a similar safety profile to ipratropium. Conclusion : This study shows that tiotropium administrated once daily has a superior bronchodilator effect with a similar safety profile in treating COPD patients compared with ipratropium, inhaled four times daily.